Cochlear (Cochlear) Current Accrued Expense : $0 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Cochlear Current Accrued Expense?

Cochlear's Current Accrued Expense for the quarter that ended in Dec. 2023 was $0 Mil.

Cochlear Current Accrued Expense Historical Data

The historical data trend for Cochlear's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cochlear Current Accrued Expense Chart

Cochlear Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Current Accrued Expense

Get a 7-Day Free Trial

Cochlear Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Current Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Cochlear Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Cochlear Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Cochlear's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Cochlear (Cochlear) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cochlear Ltd (OTCPK:CHEOF) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

CHEOY:USA OC5:Germany COH:Australia

Address

1 University Avenue, Macquarie University, Sydney, NSW, AUS, 2109

Website

https://www.cochlear.com

Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2020, 49% of revenue came from the Americas, 35% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.